Multiple Ascending Dose (MAD) Study of R4733 Administered Orally in Patients With Refractory Metastatic or Locally Advanced Solid Tumors

Inclusion Criteria:

- adult patients, >=18 years of age;

- advanced and/or metastatic solid tumor malignancy;

- measurable or evaluable disease;

- ECOG performance status 0 or 1.

Exclusion Criteria:

- prior chemotherapy, radiotherapy or immunotherapy within 28 days of first receipt of
study drug;

- prior corticosteroids as anti-cancer therapy within a minimum of 14 days of first
receipt of study drug. Dexamethasone may be allowed only as part of the supportive
care measures;

- major surgery within 28 days of first receipt of study drug.